{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T14:10:00Z","timestamp":1764252600865,"version":"3.46.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T00:00:00Z","timestamp":1760486400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T00:00:00Z","timestamp":1760486400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs Aging"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s40266-025-01258-6","type":"journal-article","created":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T06:06:53Z","timestamp":1760508413000},"page":"1159-1167","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Anti-hypertensive Drug Classes and Risk of New-Onset Atrial Fibrillation in Healthy Older Adults: A Post Hoc Analysis of ASPREE Trial"],"prefix":"10.1007","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0835-8686","authenticated-orcid":false,"given":"Zhen","family":"Zhou","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michelle A","family":"Fravel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suzanne G.","family":"Orchard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joanne","family":"Ryan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sophia","family":"Zoungas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sharyn","family":"Fitzgerald","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amy","family":"Brodtmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lawrence J.","family":"Beilin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rory","family":"Wolfe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew M.","family":"Tonkin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark R.","family":"Nelson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robyn L.","family":"Woods","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nigel","family":"Stocks","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher M.","family":"Reid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael E.","family":"Ernst","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,10,15]]},"reference":[{"issue":"2","key":"1258_CR1","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1161\/CIRCRESAHA.117.311402","volume":"122","author":"P Verdecchia","year":"2018","unstructured":"Verdecchia P, Angeli F, Reboldi G. Hypertension and atrial fibrillation: doubts and certainties from basic and clinical studies. Circ Res. 2018;122(2):352\u201368. https:\/\/doi.org\/10.1161\/CIRCRESAHA.117.311402.","journal-title":"Circ Res"},{"issue":"4","key":"1258_CR2","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1093\/europace\/eun369","volume":"11","author":"M Nabauer","year":"2009","unstructured":"Nabauer M, Gerth A, Limbourg T, et al. The Registry of the German Competence NETwork on Atrial Fibrillation: patient characteristics and initial management. Europace. 2009;11(4):423\u201334. https:\/\/doi.org\/10.1093\/europace\/eun369.","journal-title":"Europace"},{"issue":"11","key":"1258_CR3","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1001\/jama.1994.03510350050036","volume":"271","author":"EJ Benjamin","year":"1994","unstructured":"Benjamin EJ, Levy D, Vaziri SM, D\u2019Agostino RB, Belanger AJ, Wolf PA. Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study. JAMA. 1994;271(11):840\u20134.","journal-title":"JAMA"},{"issue":"16","key":"1258_CR4","doi-asserted-by":"publisher","first-page":"2146","DOI":"10.1161\/CIRCULATIONAHA.108.830042","volume":"119","author":"D Conen","year":"2009","unstructured":"Conen D, Tedrow UB, Koplan BA, Glynn RJ, Buring JE, Albert CM. Influence of systolic and diastolic blood pressure on the risk of incident atrial fibrillation in women. Circulation. 2009;119(16):2146\u201352. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.108.830042.","journal-title":"Circulation"},{"issue":"6","key":"1258_CR5","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1161\/01.hyp.25.6.1155","volume":"25","author":"SM Vaziri","year":"1995","unstructured":"Vaziri SM, Larson MG, Lauer MS, Benjamin EJ, Levy D. Influence of blood pressure on left atrial size. The Framingham Heart Study. Hypertension. 1995;25(6):1155\u201360. https:\/\/doi.org\/10.1161\/01.hyp.25.6.1155.","journal-title":"Hypertension"},{"issue":"2","key":"1258_CR6","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1136\/hrt.2004.042473","volume":"91","author":"T Kahan","year":"2005","unstructured":"Kahan T, Bergfeldt L. Left ventricular hypertrophy in hypertension: its arrhythmogenic potential. Heart. 2005;91(2):250\u20136. https:\/\/doi.org\/10.1136\/hrt.2004.042473.","journal-title":"Heart"},{"issue":"4 Pt 2","key":"1258_CR7","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1161\/01.hyp.34.4.724","volume":"34","author":"G Mancia","year":"1999","unstructured":"Mancia G, Grassi G, Giannattasio C, Seravalle G. Sympathetic activation in the pathogenesis of hypertension and progression of organ damage. Hypertension. 1999;34(4 Pt 2):724\u20138. https:\/\/doi.org\/10.1161\/01.hyp.34.4.724.","journal-title":"Hypertension"},{"key":"1258_CR8","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.3389\/fnins.2018.01058","volume":"12","author":"R Carnagarin","year":"2018","unstructured":"Carnagarin R, Kiuchi MG, Ho JK, Matthews VB, Schlaich MP. Sympathetic nervous system activation and its modulation: role in atrial fibrillation. Front Neurosci. 2018;12:1058. https:\/\/doi.org\/10.3389\/fnins.2018.01058.","journal-title":"Front Neurosci"},{"issue":"6","key":"1258_CR9","doi-asserted-by":"publisher","first-page":"972","DOI":"10.4022\/jafib.972","volume":"6","author":"GM Nair","year":"2014","unstructured":"Nair GM, Nery PB, Redpath CJ, Birnie DH. The role of renin angiotensin system in atrial fibrillation. J Atr Fibrillation. 2014;6(6):972. https:\/\/doi.org\/10.4022\/jafib.972.","journal-title":"J Atr Fibrillation"},{"issue":"6","key":"1258_CR10","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1161\/HYPERTENSIONAHA.120.14766","volume":"75","author":"EZ Soliman","year":"2020","unstructured":"Soliman EZ, Rahman AF, Zhang ZM, et al. Effect of intensive blood pressure lowering on the risk of atrial fibrillation. Hypertension. 2020;75(6):1491\u20136. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.120.14766.","journal-title":"Hypertension"},{"issue":"2","key":"1258_CR11","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1007\/s10654-022-00914-0","volume":"38","author":"D Aune","year":"2023","unstructured":"Aune D, Mahamat-Saleh Y, Kobeissi E, Feng T, Heath AK, Janszky I. Blood pressure, hypertension and the risk of atrial fibrillation: a systematic review and meta-analysis of cohort studies. Eur J Epidemiol. 2023;38(2):145\u201378. https:\/\/doi.org\/10.1007\/s10654-022-00914-0.","journal-title":"Eur J Epidemiol"},{"issue":"12","key":"1258_CR12","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1038\/s41371-019-0279-7","volume":"33","author":"J Gumprecht","year":"2019","unstructured":"Gumprecht J, Domek M, Lip GYH, Shantsila A. Invited review: hypertension and atrial fibrillation: epidemiology, pathophysiology, and implications for management. J Hum Hypertens. 2019;33(12):824\u201336. https:\/\/doi.org\/10.1038\/s41371-019-0279-7.","journal-title":"J Hum Hypertens"},{"issue":"5","key":"1258_CR13","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1161\/HYPERTENSIONAHA.117.08934","volume":"70","author":"MS Dzeshka","year":"2017","unstructured":"Dzeshka MS, Shantsila A, Shantsila E, Lip GYH. Atrial fibrillation and hypertension. Hypertension. 2017;70(5):854\u201361. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.117.08934.","journal-title":"Hypertension"},{"issue":"16","key":"1258_CR14","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1056\/NEJMoa1805819","volume":"379","author":"JJ McNeil","year":"2018","unstructured":"McNeil JJ, Wolfe R, Woods RL, et al. Effect of aspirin on cardiovascular events and bleeding in the healthy elderly. N Engl J Med. 2018;379(16):1509\u201318. https:\/\/doi.org\/10.1056\/NEJMoa1805819.","journal-title":"N Engl J Med"},{"issue":"16","key":"1258_CR15","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1056\/NEJMoa1800722","volume":"379","author":"JJ McNeil","year":"2018","unstructured":"McNeil JJ, Woods RL, Nelson MR, et al. Effect of aspirin on disability-free survival in the healthy elderly. N Engl J Med. 2018;379(16):1499\u2013508. https:\/\/doi.org\/10.1056\/NEJMoa1800722.","journal-title":"N Engl J Med"},{"issue":"2","key":"1258_CR16","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1016\/j.cct.2013.09.014","volume":"36","author":"ASPREE Investigator Group","year":"2013","unstructured":"ASPREE Investigator Group. Study design of ASPirin in Reducing Events in the Elderly (ASPREE): a randomized, controlled trial. Contemp Clin Trials. 2013;36(2):555\u201364. https:\/\/doi.org\/10.1016\/j.cct.2013.09.014.","journal-title":"Contemp Clin Trials"},{"key":"1258_CR17","doi-asserted-by":"publisher","DOI":"10.1093\/ehjcvp\/pvad082","author":"J Ball","year":"2023","unstructured":"Ball J, Neumann JT, Tonkin AM, et al. Low-dose aspirin and incident atrial fibrillation in healthy older individuals: a post-hoc analysis of the ASPREE Trial. Eur Heart J Cardiovasc Pharmacother. 2023. https:\/\/doi.org\/10.1093\/ehjcvp\/pvad082.","journal-title":"Eur Heart J Cardiovasc Pharmacother."},{"issue":"6","key":"1258_CR18","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1161\/CIRCULATIONAHA.123.067626","volume":"149","author":"SS Khan","year":"2024","unstructured":"Khan SS, Matsushita K, Sang Y, et al. Development and Validation of the American Heart Association\u2019s PREVENT Equations. Circulation. 2024;149(6):430\u201349. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.123.067626.","journal-title":"Circulation"},{"issue":"3","key":"1258_CR19","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1007\/s10654-019-00494-6","volume":"34","author":"TJ VanderWeele","year":"2019","unstructured":"VanderWeele TJ. Principles of confounder selection. Eur J Epidemiol. 2019;34(3):211\u20139. https:\/\/doi.org\/10.1007\/s10654-019-00494-6.","journal-title":"Eur J Epidemiol"},{"issue":"10","key":"1258_CR20","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.1001\/jama.296.10.1242","volume":"296","author":"PM Okin","year":"2006","unstructured":"Okin PM, Wachtell K, Devereux RB, et al. Regression of electrocardiographic left ventricular hypertrophy and decreased incidence of new-onset atrial fibrillation in patients with hypertension. JAMA. 2006;296(10):1242\u20138. https:\/\/doi.org\/10.1001\/jama.296.10.1242.","journal-title":"JAMA"},{"issue":"5","key":"1258_CR21","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1159\/000526792","volume":"31","author":"G Koracevic","year":"2022","unstructured":"Koracevic G, Perisic Z, Stanojkovic M, et al. A discrepancy: calcium channel blockers are effective for the treatment of hypertensive left ventricular hypertrophy but not as effective for prevention of heart failure. Med Princ Pract. 2022;31(5):454\u201362. https:\/\/doi.org\/10.1159\/000526792.","journal-title":"Med Princ Pract"},{"key":"1258_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacadv.2023.100382","author":"AD Kaze","year":"2023","unstructured":"Kaze AD, Yuyun MF, Fonarow GC, Echouffo-Tcheugui JB. Blood pressure variability and risk of atrial fibrillation in adults with type 2 diabetes. JACC Adv. 2023. https:\/\/doi.org\/10.1016\/j.jacadv.2023.100382.","journal-title":"JACC Adv."},{"issue":"8","key":"1258_CR23","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1038\/s41371-024-00936-z","volume":"38","author":"K Konstantinou","year":"2024","unstructured":"Konstantinou K, Apostolos A, Tsiachris D, et al. Exploring the link between blood pressure variability and atrial fibrillation: current insights and future directions. J Hum Hypertens. 2024;38(8):583\u201394. https:\/\/doi.org\/10.1038\/s41371-024-00936-z.","journal-title":"J Hum Hypertens"},{"issue":"3","key":"1258_CR24","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1097\/HJH.0000000000003033","volume":"40","author":"A de Havenon","year":"2022","unstructured":"de Havenon A, Petersen N, Wolcott Z, et al. Effect of dihydropyridine calcium channel blockers on blood pressure variability in the SPRINT trial: a treatment effects approach. J Hypertens. 2022;40(3):462\u20139. https:\/\/doi.org\/10.1097\/HJH.0000000000003033.","journal-title":"J Hypertens"},{"issue":"9192","key":"1258_CR25","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.1016\/s0140-6736(99)10327-1","volume":"354","author":"L Hansson","year":"1999","unstructured":"Hansson L, Lindholm LH, Ekbom T, et al. Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study. Lancet. 1999;354(9192):1751\u20136. https:\/\/doi.org\/10.1016\/s0140-6736(99)10327-1.","journal-title":"Lancet"},{"issue":"22","key":"1258_CR26","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.1016\/j.jacc.2009.08.020","volume":"54","author":"LJ Haywood","year":"2009","unstructured":"Haywood LJ, Ford CE, Crow RS, et al. Atrial fibrillation at baseline and during follow-up in ALLHAT (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial). J Am Coll Cardiol. 2009;54(22):2023\u201331. https:\/\/doi.org\/10.1016\/j.jacc.2009.08.020.","journal-title":"J Am Coll Cardiol"},{"issue":"18","key":"1258_CR27","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1093\/eurheartj\/eht507","volume":"35","author":"SC Marott","year":"2014","unstructured":"Marott SC, Nielsen SF, Benn M, Nordestgaard BG. Antihypertensive treatment and risk of atrial fibrillation: a nationwide study. Eur Heart J. 2014;35(18):1205\u201314. https:\/\/doi.org\/10.1093\/eurheartj\/eht507.","journal-title":"Eur Heart J"},{"issue":"6 Suppl","key":"1258_CR28","doi-asserted-by":"publisher","first-page":"S12","DOI":"10.1016\/j.hrthm.2008.02.025","volume":"5","author":"S Iravanian","year":"2008","unstructured":"Iravanian S, Dudley SC Jr. The renin-angiotensin-aldosterone system (RAAS) and cardiac arrhythmias. Heart Rhythm. 2008;5(6 Suppl):S12\u20137. https:\/\/doi.org\/10.1016\/j.hrthm.2008.02.025.","journal-title":"Heart Rhythm"},{"issue":"12","key":"1258_CR29","doi-asserted-by":"publisher","first-page":"2197","DOI":"10.1016\/s0735-1097(03)00464-9","volume":"41","author":"K Kumagai","year":"2003","unstructured":"Kumagai K, Nakashima H, Urata H, Gondo N, Arakawa K, Saku K. Effects of angiotensin II type 1 receptor antagonist on electrical and structural remodeling in atrial fibrillation. J Am Coll Cardiol. 2003;41(12):2197\u2013204. https:\/\/doi.org\/10.1016\/s0735-1097(03)00464-9.","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"1258_CR30","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1177\/1074248410395018","volume":"17","author":"R Fogari","year":"2012","unstructured":"Fogari R, Mugellini A, Zoppi A, et al. Effect of telmisartan and ramipril on atrial fibrillation recurrence and severity in hypertensive patients with metabolic syndrome and recurrent symptomatic paroxysmal and persistent atrial fibrillation. J Cardiovasc Pharmacol Ther. 2012;17(1):34\u201343. https:\/\/doi.org\/10.1177\/1074248410395018.","journal-title":"J Cardiovasc Pharmacol Ther"},{"issue":"4","key":"1258_CR31","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1161\/HYPERTENSIONAHA.111.202309","volume":"61","author":"H Du","year":"2013","unstructured":"Du H, Fan J, Ling Z, et al. Effect of nifedipine versus telmisartan on prevention of atrial fibrillation recurrence in hypertensive patients. Hypertension. 2013;61(4):786\u201392. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.111.202309.","journal-title":"Hypertension"},{"issue":"1","key":"1258_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jacc.2007.09.026","volume":"51","author":"G Casaclang-Verzosa","year":"2008","unstructured":"Casaclang-Verzosa G, Gersh BJ, Tsang TS. Structural and functional remodeling of the left atrium: clinical and therapeutic implications for atrial fibrillation. J Am Coll Cardiol. 2008;51(1):1\u201311. https:\/\/doi.org\/10.1016\/j.jacc.2007.09.026.","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"1258_CR33","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1177\/1074248415619490","volume":"21","author":"S Chaugai","year":"2016","unstructured":"Chaugai S, Meng WY, Ali SA. Effects of RAAS blockers on atrial fibrillation prophylaxis: an updated systematic review and meta-analysis of randomized controlled trials. J Cardiovasc Pharmacol Ther. 2016;21(4):388\u2013404. https:\/\/doi.org\/10.1177\/1074248415619490.","journal-title":"J Cardiovasc Pharmacol Ther"},{"issue":"15","key":"1258_CR34","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1056\/NEJMoa0801317","volume":"358","author":"S Yusuf","year":"2008","unstructured":"ONTARGET Investigators, Yusuf S, Teo KK, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358(15):1547\u201359. https:\/\/doi.org\/10.1056\/NEJMoa0801317.","journal-title":"N Engl J Med"}],"container-title":["Drugs & Aging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40266-025-01258-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40266-025-01258-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40266-025-01258-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T14:07:30Z","timestamp":1764252450000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40266-025-01258-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,15]]},"references-count":34,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["1258"],"URL":"https:\/\/doi.org\/10.1007\/s40266-025-01258-6","relation":{},"ISSN":["1170-229X","1179-1969"],"issn-type":[{"type":"print","value":"1170-229X"},{"type":"electronic","value":"1179-1969"}],"subject":[],"published":{"date-parts":[[2025,10,15]]},"assertion":[{"value":"26 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors declare that they have no conflict of interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This retrospective study was conducted using the existing data of ASPREE trial thus ethics approval is not required.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed Consent"}},{"value":"Requests for data access will be via the ASPREE Principal Investigators with details for applications provided through\n                      \n                      or\n                      \n                      .","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data Availability"}},{"value":"Study concept and design: Z.Z., M.A.F., S.G.O., A.B., M.R.N., M.E.E.; interpretation of data: all authors; statistical analysis and drafting of the manuscript: ZZ.; critical revision of the manuscript for important intellectual content: all authors; Guarantor: M.E.E.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}}]}}